Go Pro
NYSE:NSPR

InspireMD (NSPR) Stock Price, News & Analysis

InspireMD logo
$0.98 +0.14 (+16.94%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.01 +0.03 (+2.81%)
As of 08/14/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About InspireMD Stock (NYSE:NSPR)

Advanced

Key Stats

Today's Range
$0.85
$1.02
50-Day Range
$0.65
$0.98
52-Week Range
$0.63
$2.57
Volume
432,126 shs
Average Volume
155,152 shs
Market Capitalization
$46.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

InspireMD, Inc. is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets. CGuard EPS combines a self-expanding nitinol stent with an ultrathin polyethylene terephthalate (PET) MicroNet mesh, designed to trap plaque fragments and reduce the risk of peri-procedural stroke. Clinical data have demonstrated promising rates of procedural success and low incidence of embolic complications, positioning CGuard EPS as a leading choice for interventionalists in Europe, Latin America, and parts of Asia Pacific.

InspireMD was founded in 2002 and has since established a presence in key global markets outside the United States, while continuing to pursue regulatory clearance from the U.S. Food and Drug Administration. The company maintains headquarters in Tel Aviv, Israel, with additional offices in the United States to support clinical and regulatory activities. InspireMD collaborates with hospitals, research institutions, and distributors worldwide to broaden access to its stent systems and to advance the clinical evidence base for its technology.

The company is guided by a management team with seasoned expertise in interventional cardiology, neurology, regulatory affairs and medical device commercialization. InspireMD remains committed to innovation in vascular therapy and continues to invest in product development, clinical research and strategic partnerships to address unmet needs in the treatment of atherosclerotic and neurovascular diseases.

AI Generated. May Contain Errors.

InspireMD Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

NSPR MarketRank™: 

InspireMD scored higher than 52% of companies evaluated by MarketBeat, and ranked 511th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    InspireMD has a consensus price target of $4.50, representing about 358.1% upside from its current price of $0.98.

  • Amount of Analyst Coverage

    InspireMD has received no research coverage in the past 90 days.

  • Read more about InspireMD's stock forecast and price target.
  • Earnings Growth

    Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InspireMD is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InspireMD is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InspireMD has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NSPR.
  • Dividend Yield

    InspireMD does not currently pay a dividend.

  • Dividend Growth

    InspireMD does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for InspireMD this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for NSPR on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InspireMD insiders have sold 30.72% more of their company's stock than they have bought. Specifically, they have bought $17,600.00 in company stock and sold $23,006.00 in company stock.

  • Percentage Held by Insiders

    24.98% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InspireMD's insider trading history.
Receive NSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NSPR Stock News Headlines

InspireMD Inc.
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.tc pixel
InspireMD (NYSE:NSPR) Stock Price Up 0% - Should You Buy?
See More Headlines

NSPR Stock Analysis - Frequently Asked Questions

InspireMD's stock was trading at $1.78 at the beginning of the year. Since then, NSPR stock has decreased by 44.8% and is now trading at $0.9824.

InspireMD, Inc. (NYSE:NSPR) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%.

InspireMD (NSPR) raised $10,000 in an initial public offering on Friday, May 21st 2021. The company issued 2,000,000 shares at $0.00-$0.01 per share.

Top institutional shareholders of InspireMD include Parkman Healthcare Partners LLC (5.16%) and BlackRock Inc. (0.26%). Insiders that own company stock include Marvin Slosman, Shane Thomas Gleason, Gary S Roubin, Paul Stuka, Thomas J Kester and Scott R Ward.
View institutional ownership trends
.

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/12/2024
Today
8/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:NSPR
CIK
1433607
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$3.00
Potential Upside/Downside
+358.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.92 million
Net Margins
-413.96%
Pretax Margin
-413.00%
Return on Equity
-69.42%
Return on Assets
-57.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.39
Quick Ratio
6.05

Sales & Book Value

Annual Sales
$10.85 million
Price / Sales
4.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.83 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
46,839,000
Free Float
18,332,000
Market Cap
$46.01 million
Optionable
Optionable
Beta
0.81
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:NSPR) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners